Status:
COMPLETED
Does Erythropoietin Improve Outcome in Very Preterm Infants?
Lead Sponsor:
Swiss Neonatal Network
Collaborating Sponsors:
Swiss National Science Foundation
Conditions:
Intracranial Hemorrhage
Periventricular Leukomalacia
Eligibility:
All Genders
Up to 3 years
Phase:
PHASE2
Brief Summary
The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age. This s...
Detailed Description
HYPOTHESIS Early administration of human erythropoietin (EPO) in very preterm infants reduces perinatal injury to the brain (retina), lung and gut and improves neurodevelopmental outcome at 24 months ...
Eligibility Criteria
Inclusion
- Infants born between 26 0/7 and 31 6/7 gestational weeks
- Postnatal age less than 3 hours
- Informed parental consent (preferably obtained before birth)
Exclusion
- Genetically defined syndrome
- Severe congenital malformation adversely affecting life expectancy
- Severe congenital malformation adversely affecting neurodevelopment
- A priory palliative care
- Intracranial haemorrhage grade 3 or more detected before dose 3 of Erythropoietin
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT00413946
Start Date
January 1 2006
End Date
December 1 2012
Last Update
October 30 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital
Aarau, Switzerland
2
Kantonsspital
Basel, Switzerland
3
Kantonsspital
Chur, Switzerland
4
Hopital universitaire
Geneva, Switzerland